Updates in the understanding of cancer metastases, especially sentinel node biopsy concepts and technology, will be the focus of the meeting. Studies of biomarkers and their diagnostic and prognostic applications in cancer progression and metastatic cancer, as well as their usefulness in radioimaging and molecular targeted therapy will be a significant part of the Congress. Recent developments in understanding the cancer microenvironment, the molecular mechanisms involved in the progression of cancer cells to metastasis, and immune trafficking and responses to cancer cells will be explored. Results of recent clinical trials of emerging therapies will be discussed.
The Congress will bring together basic scientists, oncologists, surgeons, and radiologists from around the world, resulting in a cross-fertilization of ideas that will enhance the translation of basic science into clinical application—and challenge basic scientists with clinical issues—thus linking "the bench to the bedside."
In addition to our regular sessions, this year’s program will feature distinguished guest lectures, mini-symposia, and poster exhibits—including proffered abstract presentations from general audience abstract submission and award-winning abstracts from young investigators and trainees in the field of sentinel node biopsy and cancer metastasis.
We are confident that this 3-day CME-certified activity in San Francisco will make a significant impact by expanding the understanding and practices of oncologists involved in the management of cancer and bringing the clinical relevance of cancer metastasis to the basic scientists.
Thank you for your consideration.
Please subscribe to our Constant Contact e-mail mailing list to receive program updates and information about future programs:
|Copyright © 2012 Joint International Oncology Congress All Rights Reserved.|